BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 9215838)

  • 1. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
    Tricot G; Sawyer JR; Jagannath S; Desikan KR; Siegel D; Naucke S; Mattox S; Bracy D; Munshi N; Barlogie B
    J Clin Oncol; 1997 Jul; 15(7):2659-66. PubMed ID: 9215838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant.
    Mehta J; Tricot G; Jagannath S; Desikan KR; Siegel D; Singhal S; Munshi N; Vesole D; Mattox S; Bracy D; Barlogie B
    Bone Marrow Transplant; 1997 Jul; 20(2):113-6. PubMed ID: 9244413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
    Guo W; Zhan Y; Mery D; Siegel ER; Sun F; Cheng Y; Ashby TC; Zhang Z; Bailey C; Alapat DV; Peng H; Hadidi SA; Thanendrarajan S; Schinke C; Zangari M; van Rhee F; Tricot G; Shaughnessy JD; Zhan F
    Blood Cancer J; 2024 Feb; 14(1):30. PubMed ID: 38355688
    [No Abstract]   [Full Text] [Related]  

  • 4. Myelomatous Pleural Effusion: A Rare Occurrence in Multiple Myeloma.
    Amjad MA; Hamid Z; Ramakrishna S; Frank R; Ochieng P
    Cureus; 2022 Jun; 14(6):e26045. PubMed ID: 35859966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Serum IgG1 to Predict Progression and Therapeutic Effect in Patients with Multiple Myeloma.
    Yin J; Qiu J; Zhang Z; Feng B; Shi J; Zheng D
    J Oncol; 2022; 2022():8628781. PubMed ID: 35342422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.
    Binder M; Rajkumar SV; Ketterling RP; Greipp PT; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Hwa YL; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kyle RA; Kumar SK
    Blood Cancer J; 2017 Sep; 7(9):e600. PubMed ID: 28862698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical analysis of four multiple myeloma patients with - 13/13q- and 17p].
    Wang D; Yu F; Fang B; Song Y
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):65-7. PubMed ID: 26876257
    [No Abstract]   [Full Text] [Related]  

  • 8. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
    Terragna C; Remondini D; Martello M; Zamagni E; Pantani L; Patriarca F; Pezzi A; Levi G; Offidani M; Proserpio I; De Sabbata G; Tacchetti P; Cangialosi C; Ciambelli F; ViganĂ² CV; Dico FA; Santacroce B; Borsi E; Brioli A; Marzocchi G; Castellani G; Martinelli G; Palumbo A; Cavo M
    Oncotarget; 2016 Mar; 7(9):9666-79. PubMed ID: 26575327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid evolving into acute myeloid leukemia in a patient with multiple myeloma and concurrent myelodysplasia after VTD therapy.
    Gu ZH; Xie X; Mao JJ; Guo HF
    Int J Clin Exp Med; 2015; 8(6):10105-8. PubMed ID: 26309708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.
    Tian E; Sawyer JR; Heuck CJ; Zhang Q; van Rhee F; Barlogie B; Epstein J
    Genes Chromosomes Cancer; 2014 Jul; 53(7):549-57. PubMed ID: 24638926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.
    Lu G; Muddasani R; Orlowski RZ; Abruzzo LV; Qazilbash MH; You MJ; Wang Y; Zhao M; Chen S; Glitza IC; Medeiros LJ
    Arch Pathol Lab Med; 2013 May; 137(5):625-31. PubMed ID: 23627452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
    Bergsagel PL; Mateos MV; Gutierrez NC; Rajkumar SV; San Miguel JF
    Blood; 2013 Feb; 121(6):884-92. PubMed ID: 23165477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in myeloma stem cells.
    Cruz RD; Tricot G; Zangari M; Zhan F
    Am J Blood Res; 2011; 1(2):135-45. PubMed ID: 22432075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.
    Richardson P; Mitsiades C; Laubach J; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson K
    Core Evid; 2010 Jun; 4():215-45. PubMed ID: 20694078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.
    Mollee P
    Clin Biochem Rev; 2009 Aug; 30(3):93-103. PubMed ID: 19841691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
    Fonseca R; Bergsagel PL; Drach J; Shaughnessy J; Gutierrez N; Stewart AK; Morgan G; Van Ness B; Chesi M; Minvielle S; Neri A; Barlogie B; Kuehl WM; Liebisch P; Davies F; Chen-Kiang S; Durie BG; Carrasco R; Sezer O; Reiman T; Pilarski L; Avet-Loiseau H;
    Leukemia; 2009 Dec; 23(12):2210-21. PubMed ID: 19798094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma.
    Rajkumar SV
    Curr Probl Cancer; 2009; 33(1):7-64. PubMed ID: 19254626
    [No Abstract]   [Full Text] [Related]  

  • 18. Suppression of abnormal karyotype predicts superior survival in multiple myeloma.
    Arzoumanian V; Hoering A; Sawyer J; van Rhee F; Bailey C; Gurley J; Shaughnessy JD; Anaissie E; Crowley J; Barlogie B
    Leukemia; 2008 Apr; 22(4):850-5. PubMed ID: 18200039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse pulmonary parenchymal involvement in multiple myeloma: antemortem diagnosis.
    Kamble R; Rosenzweig T
    Int J Hematol; 2006 Apr; 83(3):259-61. PubMed ID: 16720559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
    van Rhee F; Szmania SM; Zhan F; Gupta SK; Pomtree M; Lin P; Batchu RB; Moreno A; Spagnoli G; Shaughnessy J; Tricot G
    Blood; 2005 May; 105(10):3939-44. PubMed ID: 15671442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.